From: Escitalopram in the prevention of posttraumatic stress disorder: a pilot randomized controlled trial
Total sample (N = 29) | Escitalopram (N = 12) | Placebo (N = 17) | Significance |
---|---|---|---|
Gender | |||
Male: 19 | N = 7 | N = 12 | |
Female: 10 | N = 5 | N = 5 | p = 0 .50 |
Age (mean ± SD in years) | |||
29.52 ± 8.17 | 31.33 ± 7.85 | 28.24 ± 8.38 | p = 0.32 |
Ethnicity* | |||
Black African: 23 | N = 12 | N = 11 | |
Coloured/Mixed race: 6 | N = 0 | N = 6 | p = 0.03 |
Education (mean ± SD in years) | |||
9.38 ± 2.27 | 9.25 ± 2.18 | 10.06 ± 2.82 | p = 0.41 |
Employment | |||
Yes: 16 | N = 6 | N = 10 | |
No: 13 | N = 6 | N = 7 | p = 0.64 |
Annual income (mean ± SD) | |||
$26190 ± 14483 | 30625 ± 14253 | 23462 ± 4489 | p = 0.28 |
AIS | |||
Minor: 9 | N = 5 | N = 4 | |
Moderate: 11 | N = 3 | N = 8 | |
Serious: 8 | N = 4 | N = 4 | p = 0.86 |
Trauma types | |||
Assault (physical/sexual): 20 | N = 10 | N = 10 | |
Other (mva/witnessing event): 9 | N = 2 | N = 7 | p = 0.15 |